Clarivate Plc - CLVT STOCK NEWS

BioWorld, published by Clarivate Plc (NYSE:CLVT), released an in-depth analysis on long COVID-19, affecting over 100 million globally. The report analyzes 40+ studies assessing the syndrome, developed a consensus definition for standardized research, and tracks 41 drugs in development. Despite the biotech industry's focus on COVID-19 treatments, effective therapeutics for long COVID remain scarce, with only three in late-stage trials. The social impact could be significant as researchers continue to explore disease timelines and symptoms across diverse demographics.

Clarivate Plc (NYSE:CLVT) has opened applications for the Eugene Garfield Award™, recognizing early-career scientists in citation analysis. The award, with a $25,000 unrestricted prize, aims to promote diversity and inclusion by encouraging submissions from emerging nations, especially in Africa and Asia. Established in 2017, it honors Dr. Eugene Garfield's legacy in bibliometrics. Applications are due by July 1, 2022, with the winner announced on September 1, 2022. The award seeks innovative approaches to scientific evaluation using citation data.

On February 7, 2022, Clarivate Plc (NYSE: CLVT; CLVT.PR.A) announced a $1.0 billion share repurchase program approved by its Board of Directors, set to execute through December 31, 2023. This program replaces a previous one from August 2021. Additionally, the Board declared a quarterly dividend of $1.3125 per share on its Series A Mandatory Convertible Preferred Shares, payable on March 1, 2022. Jerre Stead, CEO, emphasized the company's strong cash flow and belief in the current share price as a compelling investment opportunity.

Clarivate Plc (NYSE: CLVT) released a report on February 7, 2022, highlighting key trends shaping the medtech industry for the year. The report emphasizes innovation, healthcare decentralization, and mergers and acquisitions as pivotal factors. It notes that while recovery from COVID-19 has resumed, ongoing pressures from renewed cases may affect procedure volumes. The report also provides insights on past medtech trends and the current vaccination landscape, asserting that stakeholders must adapt to these changes for successful market engagement.

Clarivate plc (NYSE: CLVT) filed amendments to its 2020 Form 10-K and 2021 Form 10-Qs, correcting an error related to equity plan treatment in the CPA Global acquisition. The amendments restate financial results affecting income, tax provisions, net income, and shareholders' equity but do not alter GAAP revenues or key non-GAAP metrics. The revised guidance for 2022 projects revenues of $2.8B-$2.88B, adjusted EBITDA of $1.16B-$1.22B, and an organic growth rate of 6.5%. The company anticipates reporting the 2021 financial results in early March.

Clarivate Plc (NYSE:CLVT) released a report from its Institute for Scientific Information™, proposing a new method for analyzing credit attributed to academic authors via citations. As the number of collaborative research papers grows, existing credit analysis methods can become skewed. The report introduces the 'Collaborative CNCI' (Collab-CNCI) to address this issue. It emphasizes that this innovation aims to improve acknowledgment of research achievements and enhance global research collaboration. The report invites feedback from research users to evaluate Collab-CNCI's benefits compared to existing metrics.

The Patent Trend Report 2022 from Clarivate reveals a strong correlation between patent strategy and innovation, with 75% of organizations stating that patents drive further innovation. Over the past year, 69% of patent portfolios have increased, primarily due to higher budgets and executive engagement. Challenges include a lack of C-suite involvement, with 45% of respondents reporting missed opportunities. Many organizations are considering outsourcing their patent activities more, with 44% planning to increase outsourcing in the next year. The report highlights the potential of technology and AI in enhancing patent strategy.

Clarivate plc (NYSE: CLVT) announced a leadership change with Gordon Samson appointed as Chief Product Officer, effective February 1, 2022. He will focus on enhancing customer solutions across Clarivate’s verticals. Mukhtar Ahmed, the outgoing President of the Science Segment, will assist during the transition until April 1, 2022, and will remain in an advisory position until his departure on October 1, 2022. This change aims to prioritize customer-centric strategies and growth in product innovation, furthering Clarivate's One Clarivate Vision.

Clarivate Plc (CLVT) released its annual Drugs to Watch™ report, identifying seven late-stage drugs predicted to exceed $1 billion in annual sales by 2026. Key therapies include treatments for Alzheimer’s, asthma, and type 2 diabetes. The report highlights advancements in drug development despite COVID-19 disruptions, focusing on areas like mRNA, CRISPR, and AI-driven discovery. The report underscores the importance of innovative therapies in addressing significant healthcare challenges and the potential market impact of these drugs.